Cambridge Biomedical is pleased to collaborate with XenTech, a patient-derived tumor xenograft platform. Extending our offerings from target discovery through to phase three clinical trials.
Offering preclinical cancer models and services for translational drug development
To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.
XenTech Company Information
Xentech Home Page
For more information please click here to contact us